Cidara Therapeutics (NASDAQ:CDTX) CEO Jeffrey Stein acquired 212,766 shares of Cidara Therapeutics stock in a transaction that occurred on Wednesday, May 23rd. The stock was acquired at an average cost of $4.70 per share, with a total value of $1,000,000.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of CDTX traded up $0.47 during midday trading on Friday, reaching $5.90. 17,044 shares of the stock were exchanged, compared to its average volume of 143,698. Cidara Therapeutics has a 12-month low of $3.70 and a 12-month high of $8.80. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.99 and a quick ratio of 5.99. The company has a market capitalization of $111.23 million, a PE ratio of -1.76 and a beta of 2.05.
Cidara Therapeutics (NASDAQ:CDTX) last posted its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.10). equities research analysts expect that Cidara Therapeutics will post -2.86 earnings per share for the current fiscal year.
Several brokerages recently issued reports on CDTX. Cantor Fitzgerald set a $15.00 price objective on Cidara Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Zacks Investment Research downgraded Cidara Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 15th. ValuEngine downgraded Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday. Finally, WBB Securities raised Cidara Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $12.92.
Several institutional investors and hedge funds have recently bought and sold shares of CDTX. Prosight Management LP purchased a new stake in shares of Cidara Therapeutics during the 4th quarter worth about $11,206,000. BlackRock Inc. raised its stake in shares of Cidara Therapeutics by 265.0% during the 1st quarter. BlackRock Inc. now owns 249,540 shares of the biotechnology company’s stock worth $998,000 after purchasing an additional 181,177 shares in the last quarter. Guggenheim Capital LLC increased its holdings in shares of Cidara Therapeutics by 117.3% during the 1st quarter. Guggenheim Capital LLC now owns 223,903 shares of the biotechnology company’s stock valued at $895,000 after acquiring an additional 120,878 shares during the last quarter. Eversept Partners LLC acquired a new position in shares of Cidara Therapeutics during the 4th quarter valued at about $340,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Cidara Therapeutics by 26.2% during the 4th quarter. Renaissance Technologies LLC now owns 179,300 shares of the biotechnology company’s stock valued at $1,219,000 after acquiring an additional 37,197 shares during the last quarter. 62.48% of the stock is owned by institutional investors.
About Cidara Therapeutics
Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.